Summary
Machine-generated summaryNHS England has awarded contracts for the Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service and the Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service. These are one-time in vivo gene replacement therapies for spinal muscular atrophy, delivered intravenously to babies aged 12 months and under, and by intrathecal injection to patients aged 2 years and over, subject to NICE technology appraisal with expected final guidance in late 2026. The procurement was carried out in lots. The winners are Alder Hey Children's NHS FT, Great Ormond Street Hospital, Guy's and St Thomas' NHS Foundation Trust, King's College Hospital NHS FT, Leeds Teaching Hospitals NHS Foundation Trust, North Manchester General Hospital, Northern Care Alliance NHS Foundation Trust and Oxford University Hospitals NHS FT. Contract values are estimated and depend on the number of patients treated.
Description
Official source
Source: Find a Tender Service (UK Cabinet Office / Crown Commercial Service)
Always verify details on the official notice.
Report an error in this notice
Last verified against Find a Tender Service (UK Cabinet Office / Crown Commercial Service) 1 week ago
More from this buyer
Full buyer profile25 open tenders right now
- Blood Culture pathway- Health economic analysis 5 days left
- Midlands Critical Care Transfer Service Ambulance Provider 6 days left
- NHS Graduate Management Training Scheme(GMTS) Engineering and Estates Management - NHSE 8 days left
Recent awards
Similar tenders
Market context
- Avg. open tender · Health & social work
- €38,851,714
- Buyer track record on Aperlena
- 235 notices tracked · 169 awarded
- €407,038,929 in awarded contracts
Never miss a tender like this
110 new notices in Health & social work in United Kingdom in the last 7 days. Get an email when new ones appear. Free.
Set up my alert